http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016297828-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7426759b97079f689b94c12cdc610c1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C55-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C55-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-20 |
| filingDate | 2014-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_526a8c9a62dbca1d06c71c472e26ebe7 |
| publicationDate | 2016-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2016297828-A1 |
| titleOfInvention | Spirocyclic compounds containing spiro[indolyl-3,1'-pyrrolo[3,4-c]pyrrole] core and sulphur-containing amino acid residues |
| abstract | The present invention relates to spirocyclic compounds on the basis of 2-oxindole derivatives containing a spiro[indolyl-3,1′-pyrrolo[3,4-c]-pyrrole] core and biogenic sulphur-containing amino acid residues, which display a glucocorticoid-mimicking action by influencing 11β-HSD1 enzyme cortisone->cortisol conversion, or by inhibiting GRs- or GITR- or mineralocorticoid receptors, or other targets, but do not interfere with steroidal haemostasis in HPA; and compositions containing same and their use for therapy as part of undifferentiated stroke therapy (in the absence of final verification of the stroke subtype) at various stages of acute ischemic stroke (AIS), during the period of recovery from stroke and craniocerebral trauma, in patients with chronic cerebrovascular pathology (against a background of diabetes), in combinational therapy for Alzheimer's disease and encephalopathy of various origin (discirculatory, alcoholic, infectious-toxic), and diabetes, combinational therapy for retinal degenerative eye diseases, as part of combinational therapy for metabolic syndrome (obesity, in patients suffering from Cushing's syndrome, Reaven metabolic syndrome (also known as syndrome X or insulin resistance syndrome) and other diseases where GCs hormones play a key role. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2672917-C2 |
| priorityDate | 2013-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1198.